Literature DB >> 10814873

Immunocytochemical analysis of the tumour suppressor protein (p53) in feline neoplasia.

L Nasir1, H Krasner, D J Argyle, A Williams.   

Abstract

Detectable p53 immunostaining in neoplasia generally correlates with the presence of a mutation in the coding region of the p53 gene and may provide insights into the pathogenic mechanisms underlying tumourigenesis. p53 immunoreactivity was examined in 77 feline tumours, selected as a representative sample of 486 specimens submitted for diagnosis and analyzed to estimate the relative frequencies of feline neoplasias. Immunocytochemical staining demonstrated nuclear immunopositivity in 46% of the squamous cell carcinomas (SCCs), 50% of the osteosarcomas, 33% of the mammary carcinomas, 16% of the adenocarcinomas and 14% of the haemangiosarcomas. In contrast, none of the malignant lymphomas or fibrosarcomas examined showed p53 immunoreactivity. These data support a role for p53 aberrations in the pathogenesis of certain feline tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10814873     DOI: 10.1016/s0304-3835(00)00337-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa.

Authors:  Andrea Renzi; Paola De Bonis; Luca Morandi; Jacopo Lenzi; Debora Tinto; Antonella Rigillo; Giuliano Bettini; Emma Bellei; Silvia Sabattini
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

2.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

Review 3.  Cat Mammary Tumors: Genetic Models for the Human Counterpart.

Authors:  Filomena Adega; Ana Borges; Raquel Chaves
Journal:  Vet Sci       Date:  2016-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.